Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Abbott India shares dip despite profit growth, CLSA adjusts rating

EditorPollock Mondal
Published 13/11/2023, 07:40
© Reuters.

Shares of Abbott India fell nearly 3 percent Today despite the company reporting a 17 percent year-on-year increase in net profit for the second quarter of fiscal year 2024. The healthcare company's stock was traded on the National Stock Exchange (NSE) at Rs 23,197.05 this Saturday.

In its recent financial disclosure, Abbott India revealed an 8.31 percent rise in net sales to Rs 1,4914 crore for the quarter ending September 2023. Additionally, the firm experienced a significant 15.81 percent increase in EBITDA, which reached Rs 436.39 crore compared to the same period last fiscal year.

In response to these financial results, analysts at CLSA adjusted their stance on Abbott India's stock. While they downgraded the rating to 'outperform' from 'buy', they simultaneously increased their price target for the shares to Rs 27,500 per share.

This mixed reaction from the market and analysts underscores the complex interplay between company performance metrics and investor expectations. Despite Abbott India's strong profit and sales growth, the stock adjustment by CLSA suggests a recalibration of future performance projections and market positioning.

InvestingPro Insights

In a bid to provide a more comprehensive perspective on Abbott India's performance, InvestingPro has surfaced some valuable insights. According to InvestingPro's real-time data, Abbott India has a market cap of $139.49M USD and has been operating with a P/E ratio of -113.30. This suggests that the company's shares are trading at a high price relative to its earnings, highlighting its current market valuation. Additionally, the company has experienced a revenue growth of 11.35% in the last twelve months as of Q3 2023, further indicating its strong financial position.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

In terms of InvestingPro Tips, two key pointers stand out. Firstly, Abbott India yields a high return on invested capital, indicating efficient use of its resources to generate profits. Secondly, the company has consistently increased its earnings per share, pointing towards its ability to enhance shareholder value over time.

These insights are just a glimpse of what InvestingPro offers. With over 14 additional tips and extensive data available, InvestingPro serves as a reliable resource for investors seeking a deeper understanding of a company's financial performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.